ES2090696T3 - Vacunas contra infecciones de neisseria meningitidis. - Google Patents

Vacunas contra infecciones de neisseria meningitidis.

Info

Publication number
ES2090696T3
ES2090696T3 ES92921362T ES92921362T ES2090696T3 ES 2090696 T3 ES2090696 T3 ES 2090696T3 ES 92921362 T ES92921362 T ES 92921362T ES 92921362 T ES92921362 T ES 92921362T ES 2090696 T3 ES2090696 T3 ES 2090696T3
Authority
ES
Spain
Prior art keywords
receiver
recognized
neisseria meningitidis
vaccines against
molecula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92921362T
Other languages
English (en)
Inventor
Marie-Jose Quentin-Millet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Application granted granted Critical
Publication of ES2090696T3 publication Critical patent/ES2090696T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/871—Neisseria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA DE VACUNA QUE COMPRENDE COMO AGENTES TERAPEUTICOS AL MENOS UNA PRIMERA Y UNA SEGUNDA MOLECULA CAPACES DE UNIRSE A LA TRANSFERRINA HUMANA; TENIENDO DICHA PRIMERA MOLECULA POR ORIGEN UNA PRIMERA CEPA DE N.MENINGITIDIS QUE POSEE UN RECEPTOR DE LA TRANSFERRINA HUMANA CUYA SUBUNIDAD DE PESO MOLECULAR MENOR (TBP2) ES RECONOCIDA POR UN ANTISUERO ANTIRRECEPTOR DE LA CEPA N.MENINGITIDIS 2394 (RECEPTOR 2394) Y NO ES RECONOCIDA POR EL ANTISUERO ANTIRRECEPTOR DE LA CEPA DE N.MENINGITIDIS 2169 (RECEPTOR (2169); Y AL MENOS UNA SEGUNDA MOLECULA QUE TIENE POR ORIGEN UNA SEGUNDA CEPA DE N.MENINGITIDIS QUE POSEE UN RECEPTOR DE LA TRANSFERRINA HUMANA CUYA SUBUNIDAD DE PESO MOLECULAR MENOR (TBP2) ES RECONOCIDA POR UN ANTISUERO ANTIRRECEPTOR 2169 Y NO ES RECONOCIDA POR UN ANTISUERO ANTIRRECEPTOR 2394.
ES92921362T 1991-10-03 1992-09-29 Vacunas contra infecciones de neisseria meningitidis. Expired - Lifetime ES2090696T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9112177A FR2682041B1 (fr) 1991-10-03 1991-10-03 Vaccin contre les infections a neisseria meningitidis.

Publications (1)

Publication Number Publication Date
ES2090696T3 true ES2090696T3 (es) 1996-10-16

Family

ID=9417549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92921362T Expired - Lifetime ES2090696T3 (es) 1991-10-03 1992-09-29 Vacunas contra infecciones de neisseria meningitidis.

Country Status (14)

Country Link
US (1) US5618541A (es)
EP (1) EP0560968B1 (es)
JP (1) JPH06503365A (es)
AT (1) ATE140626T1 (es)
AU (1) AU662176B2 (es)
CA (1) CA2097056A1 (es)
DE (1) DE69212459T2 (es)
DK (1) DK0560968T3 (es)
ES (1) ES2090696T3 (es)
FI (1) FI107233B (es)
FR (1) FR2682041B1 (es)
HU (1) HU219673B (es)
NO (1) NO306538B1 (es)
WO (1) WO1993006861A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682114B1 (fr) * 1991-10-03 1996-02-23 Pasteur Merieux Serums Vacc Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
ES2270420T3 (es) * 1993-11-08 2007-04-01 Sanofi Pasteur Limited Genes receptores de la transferrina de haemophilus.
FR2720408B1 (fr) * 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
FR2739624B1 (fr) * 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
US6290970B1 (en) * 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6087036A (en) 1997-07-25 2000-07-11 3M Innovative Properties Company Thermal management system and method for a solid-state energy storing device
FR2767060B1 (fr) * 1997-08-07 2000-02-11 Pasteur Merieux Serums Vacc Vaccin meningocoque comportant la valence de souche bz83
RU2347813C2 (ru) * 1997-11-06 2009-02-27 Чирон С.П.А. Антигены нейссерий
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
FR2785293B1 (fr) * 1998-10-30 2002-07-05 Pasteur Merieux Serums Vacc Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
AU2004277342B2 (en) 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
ES2337309T5 (es) 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681761A (en) * 1985-10-24 1987-07-21 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
US5292869A (en) * 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same

Also Published As

Publication number Publication date
FI107233B (fi) 2001-06-29
EP0560968B1 (fr) 1996-07-24
US5618541A (en) 1997-04-08
FR2682041B1 (fr) 1994-01-14
DE69212459T2 (de) 1996-12-05
ATE140626T1 (de) 1996-08-15
AU2762492A (en) 1993-05-03
NO306538B1 (no) 1999-11-22
DK0560968T3 (da) 1996-11-25
NO932010L (no) 1993-06-02
NO932010D0 (no) 1993-06-02
FI932491A0 (fi) 1993-06-01
HUT69980A (en) 1995-09-28
EP0560968A1 (fr) 1993-09-22
HU219673B (hu) 2001-06-28
FI932491L (fi) 1993-06-01
AU662176B2 (en) 1995-08-24
JPH06503365A (ja) 1994-04-14
FR2682041A1 (fr) 1993-04-09
DE69212459D1 (de) 1996-08-29
CA2097056A1 (en) 1993-04-04
WO1993006861A1 (fr) 1993-04-15

Similar Documents

Publication Publication Date Title
ATE98870T1 (de) Avirulente mikroben und deren verwendungen.
CY1118606T1 (el) Πολυπεπτιδικα εμβολια για ευρεια παραγωγη εναντι υπερμολυσματικων μηνιγγιοκοκκιkων σειρων
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
PA8461101A1 (es) Uso de un antagonista del receptor 5-ht3 en el tratamiento del sindrome del intestino irritable (ibs)
ES2179105T3 (es) Adyuvantes proteinicos.
ES2121820T3 (es) Vacuna de conjugados de polisacaridos de neumococos.
DE69331495D1 (de) Impfstoffe gegen neisseria meningitidis gruppe c
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
BR0113822A (pt) Vacina
DE69226431D1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
FI932491A0 (fi) Vaccin mot Neisseria meningitidis-infektioner
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
BRPI0411875A (pt) método de imunização contra os sorogrupos a e c de neisseria meningitidis
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2104535T1 (es) Vacuna que contiene proteina de membrana externa de bordetella pertussis, y metodo para elaborar tal vacuna.
ES2126616T3 (es) Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
ES2128358T3 (es) Vacuna que comprende una subunidad de receptor de transferrina humana aislada de neisseria meningitidis.
BR9611455A (pt) Compostos e métodos para a detecção e prevenção de infecção por t. cruzi.
ES2038064B1 (es) Instalacion portatil de vacunacion aviar.
PE20040706A1 (es) Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca
Lucioni et al. I costi dell’influenza in Italia
ES2118720T3 (es) Produccion y utilizacion de agentes antihelminticos e inmunogenos protectores.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 560968

Country of ref document: ES

FG2A Definitive protection

Ref document number: 560968

Country of ref document: ES